{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:12:54Z","timestamp":1792087974420,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.clml.2018.08.018","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T14:53:57Z","timestamp":1536159237000},"page":"29-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and\/or Refractory CD\u201356-positive Multiple Myeloma"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Vescio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mecide","family":"Gharibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Bojanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.08.018_bib1","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2018.08.018_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.018_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2018.08.018_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.08.018_bib5","doi-asserted-by":"crossref","first-page":"f3863","DOI":"10.1136\/bmj.f3863","article-title":"Multiple myeloma","volume":"346","author":"Smith","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2018.08.018_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2141.2012.09124.x","article-title":"Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups","volume":"158","author":"Ailawadhi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.018_bib7","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/cncr.31237","article-title":"Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: a comprehensive look at racial disparities","volume":"124","author":"Ailawadhi","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.08.018_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2018.08.018_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.6004\/jnccn.2014.0055","article-title":"Advances in supportive care for multiple myeloma","volume":"12","author":"Raje","year":"2014","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2018.08.018_bib10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2018.08.018_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.08.018_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.08.018_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.08.018_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.08.018_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40259-016-0165-6","article-title":"Management of multiple myeloma with second-generation antibody-drug conjugates","volume":"30","author":"Robak","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.clml.2018.08.018_bib16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/13543784.2014.908184","article-title":"Current phase II antibody-drug conjugates for the treatment of lymphoid malignancies","volume":"23","author":"Robak","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2018.08.018_bib17","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.clml.2018.08.018_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4161\/mabs.27756","article-title":"Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models","volume":"6","author":"Whiteman","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.clml.2018.08.018_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10637-016-0336-9","article-title":"Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors","volume":"34","author":"Shah","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2018.08.018_bib20","series-title":"Antibody-drug conjugates and immunotoxins: from pre-clinical development to therapeutic applications, cancer drug discovery and development","first-page":"273","article-title":"Targeting CD56 (NCAM)-expressing neoplasms with lorvotuzumab mertansine","author":"Lambert","year":"2013"},{"key":"10.1016\/j.clml.2018.08.018_bib21","first-page":"1174","article-title":"Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed\/refractory CD56-positive multiple myeloma","volume":"110","author":"Chanan Khan","year":"2007","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2018.08.018_bib22","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.V116.21.1934.1934","article-title":"Phase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed\/refractory mulitple myeloma - a preliminary safety and efficacy analysis of the combination","volume":"116","author":"Berdeja","year":"2010","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2018.08.018_bib23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.018_bib24","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.2147\/OTT.S94531","article-title":"Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date","volume":"9","author":"Weisel","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2018.08.018_bib25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.08.018_bib26","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","article-title":"Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed\/refractory multiple myeloma","volume":"53","author":"Wolf","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.08.018_bib27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.018_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.018_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A\u00a0phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.018_bib30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.018_bib31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","article-title":"An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma","volume":"12","author":"Jagannath","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.08.018_bib32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2002.03258.x","article-title":"Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma","volume":"116","author":"Dahl","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.018_bib33","first-page":"3647","article-title":"Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization","volume":"55","author":"Pellat-Deceunynck","year":"1995","journal-title":"Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:23Z","timestamp":1761870743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018311224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2152265018311224"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and\/or Refractory CD\u201356-positive Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}